Afatinib
- PDF / 169,527 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 10 Downloads / 176 Views
1 S
Multiple toxicities: case report A 63-year-old man developed grade 1 paronychia, grade 1 stomatitis, fever and obstructive pulmonary disease during treatment with afatinib for squamous cell lung cancer. The man was diagnosed with squamous cell lung carcinoma stage-IV in December 2017. Later, he developed multiple hepatic metastatic lesions. He started receiving first line treatment with carboplatin 495mg on day 1 and gemcitabine 1.6g on day 1 and day 8. However, treatment failure was observed due to progression of the disease and he was switched to nidaplatin 40 mg/day (day 1–3) and docetaxel 120mg on day 1 as a second-line therapy in May 2018. But, the disease relapsed in July 2018. After failure of the second-line chemotherapy, he started receiving afatinib 40 mg/day [route not stated] from 07 July 2018. Within a month of initiation of afatinib, he developed afatinib-related adverse-events of grade 1 paronychia and grade 1 stomatitis. The man’s adverse-events subsided subsequently without any treatment and without discontinuation of afatinib. He also developed obstructive pulmonary disease and fever during the treatment. At the latest follow-up visit, he showed no disease progression, and afatinib treatment was continued. Lin L, et al. Response to afatinib in a patient with non-small cell lung cancer harboring HER2 R896G mutation: A case report. OncoTargets and Therapy 12: 10897-10902, 12 803445759 Dec 2019. Available from: URL: http://doi.org/10.2147/OTT.S228726
0114-9954/20/1787-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 18 Jan 2020 No. 1787
Data Loading...
